Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

h occurred in the placebo group, no SAEs of seizure were reported and the number of neuropsychiatric SAEs in lorcaserin patients did not exceed the number in the placebo group.

Cardiovascular Safety

The integrated BLOOM and BLOSSOM echocardiography data set rules out a risk of valvulopathy in lorcaserin patients according to criteria requested by the FDA. Echocardiographic evaluations showed no association between lorcaserin and the development of heart valve insufficiency. Rates of new FDA-defined valvulopathy in BLOSSOM at Week 52 were as follows: lorcaserin 10 mg twice daily (2.0%), 10 mg once daily (1.4%) and placebo (2.0%).

"The echocardiographic safety data show no risk of valvulopathy," commented Neil J. Weissman, M.D., Director, Cardiac Ultrasound and Ultrasound Core Labs, President, MedStar Research Institute, and Professor of Medicine, Georgetown University. "In the individual and combined BLOOM and BLOSSOM data sets there is no evidence of a difference in the development of valve disease in lorcaserin patients versus control for up to two years of continuous use. No prospective echocardiographic program has ever studied this many patients for this period of time."

Secondary Endpoints

Treatment with lorcaserin over one year was associated with significant improvements or strongly favorable trends compared to placebo in multiple secondary endpoints, including blood pressure and lipids.

Patient Disposition

BLOSSOM evaluated 4,008 patients with an average body mass index, or BMI, of 35.9 and baseline weight of 220 pounds. The Week 52 completion rate was higher for patients on lorcaserin 10 mg twice daily (57.2%) and 10 mg once daily (59.0%) compared to patients on placebo (52.0%). Discontinuations for adverse events were low and as follows: lorcaserin 10 mg twice daily (7.2%), 10 mg once daily (6.2
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... 25, 2014  AMETEK, Inc. (NYSE: AME ... Goos as Vice President and General Manager, Engineered ... (EMIP) Division. "I am pleased that Kurt ... business development experience, especially in the medical device industry, ... the continued growth and success of our medical components ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... 16, 2011  Mylan Inc. (Nasdaq: MYL ) ... received final approval from the U.S. Food and Drug ... for Metoprolol Succinate Extended-release (ER) Tablets USP, 25 mg, ... is the generic version of AstraZeneca,s Toprol-XL ® ...
... Medical Technologies announced today the release of its ... view used to navigate multiple planes simultaneously. This ... pulmonology, enabling physicians to view the location of ... view without any radiation being delivered to the ...
Cached Medicine Technology:Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View 2
(Date:7/25/2014)... A new study of participants in the ... published today in Cancer , found evidence that men ... had an abnormal finding on a lung cancer screening test ... than did those who were screened and found to be ... the researchers. “We expected that participants with an abnormal finding ...
(Date:7/25/2014)... July 25, 2014(BRONX, NY)A study involving nearly 27,000 older ... 10 met criteria for pre-dementia based on a simple ... they have cognitive complaints. People who tested positive for ... dementia within 12 years. The study, led by scientists ... Yeshiva University and Montefiore Medical Center , was ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Drexel University ... D. Weber, MD, MS, FACP, has been appointed vice dean ... will join Drexel from The Commonwealth Medical College, where she ... dean for clinical affairs, and professor of medicine. , ... Commonwealth Medical College, Weber had a major role in many ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Babies seem to ... By the time women are 34 weeks pregnant, ... their mother,s voice reciting a familiar nursery rhyme, the ... source of sensory stimulation in the developing fetus," Charlene ... of Florida,s College of Nursing, said in a university ...
(Date:7/25/2014)... A new system that sent patients to designated cardiac ... of sudden cardiac arrest in Arizona, according to a ... Emergency Medicine . , "We knew lives would ... edge guidelines for post-cardiac arrest care and we were ... similar to what is done for Level 1 trauma ...
Breaking Medicine News(10 mins):Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3
... RICHMOND, Va., Nov. 20 Virginia Health Information,s (VHI) ... hospitals, nursing facilities and other providers. VHI,s 2008 ... on their costs, profits, staff hours per admission, charity care and ... hospitals continued their trend of increased charity care with over 1 ...
... Nov. 20 The College of American Pathologists ... announce it has awarded the CAP 15189(SM) Accreditation ... accreditation is based on the International Organization for ... quality management and focuses on improved patient safety ...
... Indulging with less guilt is easy this holiday season. Simply substitute ... replace "naughty" saturated fat with "nice" unsaturated fat. This especially applies ... , Use canola oil in recipes that ... loaves and muffins, says Shirley Corriher, author of the new ...
... Taylor, M.D. and Christine Whitelaw, M.D. demonstrate laser hair removal ... ... Lake City, Utah (Vocus) November 20, 2008 -- With laser technology, beauty ... are now commonplace: an essential accessory in the medi-spa, offering a range ...
... National Capital Philanthropy Day Awards , ... ... Lintott, chairman of the board of the Children,s Hospital Foundation ... Volunteer" at the National Capital Philanthropy Day Awards presented by ...
... and comparison tool takes the guesswork out of Medicare Part D Plan ... ... 20, 2008 -- Drugs.com ( www.drugs.com ), the leading online ... of its new Medicare Part D Guide and Plan Selector Tool to ...
Cached Medicine News:Health News:Health Care Transparency Report Ranks Hospitals and Nursing Facilities on Efficiency and Productivity - Charity Care and Profits Increase 2Health News:Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab 2Health News:Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab 3Health News:Baking Expert Puts Health in the Holidays With Canola Oil 2Health News:Laser Beam Beauty: 'The Complete Guide to Laser Hair Removal' DVD released by Aesthetic VideoSource 2Health News:James W. Lintott Named Outstanding Fundraising Volunteer Of The Year 2Health News:Drugs.com Helps Seniors Reduce Their Prescription Drug Costs 2
For enucleation/evisceration....
... has received the FDA approval to market ... in enucleation procedures in the United States. ... strong, non-brittle biomaterial alumina (AL2, O3), and ... 500m in size. The vicryl (polyglactin 910) ...
Designed for the clockwise one-hand implantation of the Morcher Capsular Tension Ring....
...
Medicine Products: